<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584165</url>
  </required_header>
  <id_info>
    <org_study_id>NSR-CHM-OS2</org_study_id>
    <nct_id>NCT03584165</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy Follow-up of AAV2-REP1 for the Treatment of Choroideremia (SOLSTICE)</brief_title>
  <acronym>SOLSTICE</acronym>
  <official_title>A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects With Choroideremia Treated Previously With Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NightstaRx Ltd, a Biogen Company</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NightstaRx Ltd, a Biogen Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term follow up evaluating the safety and efficacy of AAV2-REP1 used in
      antecedent choroideremia studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective and part retrospective, multi-centre, observational, follow-up study
      for subjects who have previously received a sub-retinal injection of AAV2-REP1 for the
      treatment of choroideremia in an antecedent study. No further gene therapy will be given in
      this protocol. Subjects will rollover into the current study when they complete the
      antecedent study. The study will consist of up to 9 visits over a maximum 48-month study
      period.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Incidence of treatment emergent adverse events (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>up to 5 years</time_frame>
    <description>EDTRS Visual Acuity Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundus Autofluorescence (AF)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Change in AF (mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherence Tomography</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Ellipsoid Zone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Change in Sensitivity (dB)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Choroideremia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAV2-REP1</intervention_name>
    <description>Sub-retinal injection of AAV2-REP1 after vitrectomy.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients previously treated with AAV2-REP1 in an antecedent study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are willing and able to give informed consent for participation in the study.

          -  Have received a sub-retinal injection of AAV2-REP1 for CHM in an antecedent study.

        Exclusion Criteria:

          -  There are no exclusion criteria for this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>TÃ¼bingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NightstaRx</keyword>
  <keyword>NSR-REP1</keyword>
  <keyword>Choroideremia</keyword>
  <keyword>CHM</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>AAV</keyword>
  <keyword>REP1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

